Jasper Therapeutics (Jasper Therapeutics) Pre-Tax Income : $-63.93 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Jasper Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Jasper Therapeutics's pretax income for the three months ended in Mar. 2024 was $-13.73 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-63.93 Mil. Jasper Therapeutics's pretax margin was %.

Jasper Therapeutics Pre-Tax Income Historical Data

The historical data trend for Jasper Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jasper Therapeutics Pre-Tax Income Chart

Jasper Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

-31.67

-30.64

-37.69

-64.47

Jasper Therapeutics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Pre-Tax Income	Get a 7-Day Free Trial										-14.26	-16.08	-17.54	-16.58	-13.73

Competitive Comparison of Jasper Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Jasper Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jasper Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jasper Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Jasper Therapeutics's Pre-Tax Income falls into.

Jasper Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Jasper Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-68.861	+	-0.803	+	0	+	5.199	+	0
	=	-64.47

Jasper Therapeutics's Pretax Income for the quarter that ended in Mar. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-15.072	+	-0.042	+	0	+	1.386	+	0
	=	-13.73

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-63.93 Mil.

Jasper Therapeutics (NAS:JSPR) Pre-Tax Income Explanation

Jasper Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-13.728	/	0
	=	%

Jasper Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Jasper Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Jasper Therapeutics (Jasper Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jasper Therapeutics Inc (NAS:JSPR) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

2200 Bridge Parkway, Suite No. 102, Redwood, CA, USA, 94065

Website

https://www.jaspertherapeutics.com

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

Executives

Thomas G Wiggans	director
William Lis	director	PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Jeetinder Singh Mahal	officer: Chief Operating Officer	C/O JASPER THERAPEUTICS, INC., 2200 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Ron Martell	director, officer: President, CEO & Director	PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Herb Cross	officer: Chief Financial Officer	3061 ZANKER RD, SAN JOSE CA 95134
Scott C. Brun	director	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Edwin Jonathan Tucker	officer: Chief Medical Officer	C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Anna Louise French	director	C/O QIMING U.S. HEALTHCARE, 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Kurt Von Emster	director, 10 percent owner	601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080
Gary E Rieschel	10 percent owner
Qiming U.s. Healthcare Fund Ii, L.p.	10 percent owner	350 106TH AVENUE NE, 1ST FLOOR, BELLEVUE WA 98004
Llp Abingworth	10 percent owner	38 JERMYN STREET, LONDON X0 SW1Y 6DN
Mark Mcdade	10 percent owner	C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040
Qiming U.s. Healthcare Gp Ii, Llc	10 percent owner	11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Carlyle Group Inc.	10 percent owner	C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004